Skip to contentR
REGENXBIO Inc.
R
RGNXREGENXBIO Inc. Q2 2018 · 10-Q
Revenue$40.03M$40.03M+510.0% vs Q2 2017 Net Income$10.59M$10.59MN/M vs Q2 2017 EPS Diluted$0.30$0.30N/M vs Q2 2017 Operating Income$6,350,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
REGENXBIO Inc. · CIK 1590877 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$67,538,000N/M Margins · derivedOperating margin15.9%+245.3 pt vs Q2 2017
Net margin26.5%+247.0 pt vs Q2 2017
ended Jun 30, 2018 · filed Aug 8, 2018 · 39 d after period end